Сrystagen
(LMIT) with ConA).
Studies have shown that 90% of people living in an ecologically unfavorable area have immune status
disorders in the form of a decrease in the number of CD3+, CD4+ cells, with a slight increase in
lymphocytes with the CD8+ phenotype, which indicates a decrease in the level of immunoreactivity
(CD4+/CD8+). The results of LMIT with ConA characterize a decrease in the functional activity of
T-lymphocytes (mainly CD8+, i.e., T-suppressors/killers). The number of CD20+ -cells, representing a
subpopulation of B-lymphocytes, was not significantly different from normal values, but, at the same
time, there was an increase in the number of M and G immunoglobulins in blood serum (Table 2).
It should be noted that the quantitative indicators of the content of CD3+ and CD4+ cells are typical
for lower limits of physiological fluctuations in their number in patients of such age, which may indicate
premature aging of the immune system. As a rule, people with a secondary immune-deficiency condition
have a pronounced asthenic syndrome and significant changes in the cardiovascular system.
CRYSTAGEN® influence of the cellular and humoral immunity parameters in Table 2
patients, who have been exposed to low doses of ionizing radiation
Parameter Before treatment After treatment with general After treatment using Crystagen®
purpose medication
Leucocytes, ×109/l 5,1± 5,2±0,5 5,4±0,3
Lymphocytes, % 28,1±2,2 29,7±2,1 32,1±1,8
×109/l 1,62±0,03 1,56±0,06 1,67±0,04
CD3+, % 45,1±2,1 49,3±2,3 53,3±2,2*
×109/l 1,50±0,03 1,61±0,02 1,77±0,03*
CD4+, % 26,3±2,4 29,7±2,4 32,1±1,8*
×109/l 0,44±0,02 0,47±0,04 0,56±0,05*
CD8+, % 26,4±1,5 25,7±1,6 24,9±1,8
×109/l 0,43±0,05 0,42±0,03 0,46±0,07
CD4+/CD8+
1,0 1,1 1,2
CD20+, % 12,2±0,5 12,1±0,2 12,2±0,6
×109/l 0,20±0,02 0,22±0,01 0,21±0,01
Leukocytemigrationinhibitiontest, % 86,3±4,7 74,7±4,2* 71,9±4,4*
IgM, (g/l) 1,76±0,03 1,69±0,06 1,74±0,02
IgG, (g/l) 15,1±1,2 15,4±1,4 15,2±1,5
IgА, (g/l) 2,0±0,2 2,1±0,1 2,1±0,2
* Р<0,05 – significantly compared to the indicator before treatment.
The results of the studies conducted convincingly indicate that CRYSTAGEN® is an effective remedy
for correcting secondary immune deficiency that develops in response to the influence of extreme
factors. The use of KRYSTAGEN® in combination with symptomatic agents made it possible to nor-
malize the impaired parameters of the immune system in 78% of cases.
According to the data provided, the greatest effect from the use of CRYSTAGEN® was identified in
subpopulations of T-lymphocytes and their functional activity (a significant increase in the number of
CD3+ and CD4+ lymphocytes, normalization of the CD4 /CD8+ ratio). A less distinct reaction was
noticed in the B-system, probably, due to its higher conservativity.
After the course of treatment using CRYSTAGEN®, patients who received small doses of ionizing
radiation noted a significant improvement in their general condition and a decrease in the severity of
the asthenic syndrome, which always accompanies secondary immunodeficiencies.
Для таблиц, дозировок и примечаний сверяйтесь с оригинальным PDF: при извлечении текста порядок колонок может измениться.
Из библиотеки Peptides. Авторство и содержание оригинала сохранены. Размещено с разрешения поставщика.